# A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

> **NCT00319332** · PHASE3 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Lymphoma, Small Cleaved-Cell, Follicular
- Lymphoma, Large-Cell, Follicular
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Ibritumomab Tiuxetan
- **DRUG:** Iodine I 131 Tositumomab

## Key facts

- **NCT ID:** NCT00319332
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2005-09
- **Primary completion:** 2021-02
- **Final completion:** 2021-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study has been cancelled prior to enrollment
- **Last updated:** 2015-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00319332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00319332, "A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00319332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*